Digistain

01/04/2026

Digistain at South Summit Brazil 2026 | EUREKA Investment Readiness Program

We were honoured to attend South Summit Brazil 2026 as part of the EUREKA Investment Readiness Programme, where we were provided with a valuable platform to engage with investors, partners, and the wider innovation ecosystem.

As we progress a bridge round to support our next phase of growth ahead of a planned Series A, the event created meaningful opportunities to connect with investors aligned to our vision of enabling more equitable and sustainable cancer care.

With over 200,000 new breast cancer diagnoses annually, Latin America represents an important and rapidly evolving market, where improving access to cost-effective risk stratification has the potential to deliver significant clinical and system-level impact. As we continue to expand our presence in the region through our growing distributor network in Brazil, the event also facilitated a number of important commercial discussions, supporting the acceleration of our regional commercial strategy.

Thank you to the EUREKA Network for supporting our participation.

We look forward to building on these conversations and continuing to drive forward our global expansion.

18/03/2026

Digistain Engages with Global Health Leaders at Thailand BOI Roundtable

Digistain was pleased to be represented at the Thailand Board of Investment roundtable hosted at the Thai Embassy in London.

The evening brought together leaders from healthcare, investment, and policy, including the Director of the Thailand Board of Investment and the Thai Ambassador to the UK, to discuss opportunities for collaboration and innovation.

As global interest in advanced oncology solutions continues to grow, conversations like these play an important role in shaping partnerships that can improve patient outcomes across regions.

We look forward to continuing our engagement in Southeast Asia and exploring opportunities to bring innovative solutions to new markets.

04/03/2026

Digistain announces partnership with Rhythm Biosciences to distribute geneType® across Southeast Asia

We are delighted to announce that Digistain has secured the rights to distribute geneType across Southeast Asia.

Developed by publicly listed Australian company Rhythm Biosciences, geneType is a next-generation risk assessment platform which predicts an individual’s likelihood of developing various cancers and chronic diseases. By integrating genetic data with clinical factors and family history, it allows for a more comprehensive view of disease susceptibility.

Through our established supply chain networks and growing commercial footprint in the region, we aim to accelerate availability of geneType's genetic test portfolio to healthcare providers and patients across Southeast Asia, broadening access to innovative diagnostics where it's needed most.

This partnership marks an important strategic milestone for both organisations, deepening our mutual commitment to personalised, equitable healthcare. With extensive clinical networks already in place, we are uniquely positioned to bring this technology to patients at scale.

Together our complementary strengths and shared vision bring us one step closer to making precision healthcare accessible to all.

To read more about the partnership, you can access the full press release here: https://rhythmbio.com/investor-center/

We appreciate your interest in Rhythm Biosciences and invite you to explore how we’re working to create long-term value for patients and shareholders alike.

18/02/2026

We’re delighted to share that we’ve been selected as one of just 27 companies by the EUREKA Investment Readiness Network to participate in a mission to South Summit Brazil, taking place from 25 to 27 March.

As part of a competitive assessment process, companies were evaluated on their ability to address a clear unmet clinical need, demonstrate strong market alignment and real-world scalability to translate innovation into sustained commercial impact.

This recognition marks an important milestone for Digistain, reinforcing confidence in our technology’s potential to deliver meaningful and accessible change for breast cancer patients worldwide.

South Summit Brazil is one of Latin America’s leading innovation and investment events, and we’re especially pleased to share that we have also been selected as one of 12 companies to participate in a dedicated pitching session, highlighting our investability and regional expansion potential.

Alongside the pitching session, we will be showcasing Digistain at our exhibition booth, where we look forward to sharing more about the technology and our plans for expansion across Latin America.

If you’re attending South Summit Brazil, we would love to connect and we hope to see you there!

14/11/2025

Digistain Sees Rapid Clinical Uptake across South Africa

We are proud to announce that following the official launch of Digistain in South Africa last month, the technology has already been successfully integrated into routine clinical practice by local oncologists.

Why this matters: remains the most common cancer among South African women, accounting for about 22.6% of all female cancers and 16% of cancer related deaths in women. In 2022 alone, more than 14,700 new breast cancer cases were identified in South Africa.

Through informed choices, our early adopters are already seeing the impact of faster decision making and improved alignment of patient care, helping make a meaningful difference for patients where they need it most.

Thank you to all our clinical partners, teams and advocates who are helping bring this into practice across South Africa. We look forward to building on this progress as we continue to support all women living with breast cancer in this region.

08/04/2025

Dr. Hemmel Amrania, CEO of Digistain, will be delivering a keynote at the AI4Health.Cro Consortium Annual Conference today, April 8th, 2025, at the Hotel Zonar, Zagreb. This key event showcases the transformative potential of artificial intelligence in revolutionizing healthcare, with a special focus this year on enhancing breast cancer diagnostics. Dr. Hemmel Amrania's presentation, titled “The Journey of Digistain from Academia to Global Markets”, will focus on the role of artificial intelligence in revolutionizing breast cancer diagnostics and the journey from Academic theory to Global Market product commercialization.

24/03/2025

At Digistain, we’re dedicated to making reliable breast cancer risk stratification accessible to everyone.

We’re excited to highlight some of the key features of the Digistain test that could make a real difference for you or your patients.

To learn more about how Digistain could help, visit our website: https://digistain.co.uk

Or contact us at:

Phone: +44 20 3951 9812
Email: contact@digistain.co.uk

Together, we can improve outcomes in the fight against breast cancer.

04/03/2025

We're excited to share that Digistain is now being used by patients covered by one of the top four health insurers in the U.S.

This marks a huge step forward in making precision cancer diagnostics more accessible. With insurance coverage in place, more patients can benefit from precise risk stratification, helping oncologists make informed treatment decisions faster and more affordably.

A big thank you to our incredible team, partners, and supporters who make this progress possible!

12/02/2025

We were delighted to have Dr. Mel Valerie Cruz-Ordinario present to doctors at St. Luke’s Medical Center Quezon City, Philippines, sharing her specialist insight on the benefits of Digistain for precision risk stratification in breast cancer patients.

A big thank you to Dr. Cruz-Ordinario and the team at St. Luke’s for an engaging and impactful session, and for being part of our mission to improve patient care!

04/02/2025

This World Cancer Day 2025, we proudly reaffirm our commitment to transforming cancer care through innovation and compassion.

This year’s theme, “United by Unique,” reminds us that every patient’s cancer journey is as individual as they are, and highlights the importance of recognising each person’s unique circumstances, needs, and experiences.

At Digistain, we are dedicated to advancing personalised treatment—because no two patients are the same. By providing clinicians with precise, actionable insights, we aim to empower patients to take an active role in the decisions surrounding their care, ensuring their voice is at the heart of their treatment journey.

Together, we can create a future where cancer care is not only innovative but also deeply human-centered. Let’s unite to make this vision a reality.

29/01/2025

We were honored to recently host Professor Samuel Haryono from the Siloam Group Indonesia during his visit to the Digistain research lab at Imperial College London.

This visit provided an incredible opportunity to showcase some of the innovative research we’re working on to further advance the Digistain assay and make precision diagnostics more accessible and cost-effective for patients worldwide.

With Indonesia’s population of over 270 million people, improving access to accurate and affordable cancer diagnostics is more critical than ever. We had the chance to discuss this, our shared commitment to improving patient outcomes and our vision for advancing cancer care through cutting-edge technology.

We look forward to fostering even more connections like these as we continue striving to transform cancer diagnostics and care worldwide.

22/01/2025

Did you know?

Digistain was incubated at Imperial College London, where it continues to operate its research and development lab. Founded in 1907, Imperial is renowned for its excellence in science, engineering, medicine, and business. The institution ranks #1 in the UK and Europe and #2 globally according to the QS World Rankings 2025.

At Digistain, we are proud to be part of such a world-leading research environment, pushing the boundaries of innovation.